CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Queen Mary University of London
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de Queen Mary University of London (17)
2024
-
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals
Neurology and Therapy, Vol. 13, Núm. 4, pp. 1015-1038
2023
-
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21
-
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Digital Health, Vol. 9
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13
-
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Multiple Sclerosis and Related Disorders, Vol. 69
-
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
Advances in Therapy, Vol. 40, Núm. 12, pp. 5131-5136
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants
Multiple Sclerosis and Related Disorders, Vol. 64
-
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456
-
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
Multiple Sclerosis Journal
2021
-
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Therapeutic Advances in Neurological Disorders, Vol. 14
-
Multiple sclerosis progression discussion tool usability and usefulness in clinical practice: Cross-sectional, web-based survey
Journal of Medical Internet Research, Vol. 23, Núm. 10
2019
-
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
Advances in Therapy, Vol. 36, Núm. 11, pp. 3238-3252
2018
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
The Lancet, Vol. 391, Núm. 10127, pp. 1263-1273
-
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
Multiple Sclerosis and Related Disorders, Vol. 19, pp. 153-160
2015
-
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group
Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 3, pp. 202-218